Key facts
- This page summarizes Priti Patel's Form 4 filing for Neoleukin Therapeutics, Inc. (NGNE).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Apr 2023, 20:51.
Priti Patel - 31 Mar 2023 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)
- Reporting relationship
- Former Chief Medical Officer
- Issuer ticker
- NGNE
- Reported as of
- 31 Mar 2023
- Net transaction value
- -$2,608
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2023, 20:51:03 UTC
- Prior SEC filing
- 03 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Smith, as Attorney-in-Fact for Priti Patel
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Priti Patel filed Form 4 for Neoleukin Therapeutics, Inc. (NGNE) on 04 Apr 2023.
Change
- Previous filing in this sequence was filed on 03 Feb 2023.
- Current net transaction value: -$2,608.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NLTX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +32%
- Price
- $0.000000
- Shares after
- 41,082
- Date
- 31 Mar 2023
- Ownership
- Direct
NLTX
transaction
Common Stock
Sale
- Transaction value
- $2,608
- Shares
- -3,769
- Change %
- -9.2%
- Price
- $0.6919
- Shares after
- 37,313
- Date
- 03 Apr 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NLTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 31 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $0.000000
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Priti Patel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Footnote F2
Represents the weighted average sale price. The lowest price at which shares were sold was $0.6831 and the highest price at which shares were sold was $0.6980. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Footnote F3
Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F4
The RSUs vested as to 1/2 of the total number of shares underlying the award on April 30, 2022 and the remainder of the RSUs vested on March 31, 2023 pursuant to an agreement between the Reporting Person and the Issuer.
Footnote F5
The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.